<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Eterna Therapeutics Inc — News on 6ix</title>
    <link>https://6ix.com/company/eterna-therapeutics-inc</link>
    <description>Latest news and press releases for Eterna Therapeutics Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Fri, 20 Feb 2026 14:05:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/eterna-therapeutics-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835641f78dffbe2df0ef88b.webp</url>
      <title>Eterna Therapeutics Inc</title>
      <link>https://6ix.com/company/eterna-therapeutics-inc</link>
    </image>
    <item>
      <title>Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series</title>
      <link>https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-to-participate-in-virtual-investor-closing-bell-series</link>
      <guid isPermaLink="true">https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-to-participate-in-virtual-investor-closing-bell-series</guid>
      <pubDate>Fri, 20 Feb 2026 14:05:00 GMT</pubDate>
      <description>Live video webcast with Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, on Wednesday, February 25th at 4:00 PM ET Register here CAMBRIDGE, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that Sanjeev Luther, President &amp; CEO of Ernexa, will participate in the Virtual Investor Closing Bell Series on Wednesday,</description>
    </item>
    <item>
      <title>Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering</title>
      <link>https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-announces-pricing-10-142500616</link>
      <guid isPermaLink="true">https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-announces-pricing-10-142500616</guid>
      <pubDate>Fri, 06 Feb 2026 14:25:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics Inc. (Nasdaq: ERNA) (“Ernexa” or the “Company”), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the pricing of a best-efforts registered public offering of 21,000,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 21,000,000 shares of common stock, at a combined public offering price of</description>
    </item>
    <item>
      <title>Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA</title>
      <link>https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-participates-virtual-investor-134500073</link>
      <guid isPermaLink="true">https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-participates-virtual-investor-134500073</guid>
      <pubDate>Tue, 03 Feb 2026 13:45:00 GMT</pubDate>
      <description>Access the “What This Means” segment here CAMBRIDGE, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it recently participated in a Virtual Investor &quot;What This Means&quot; segment discussing the Company’s recent successful Pre-IND meeting with the U.S. Food and Drug Administration and its continued advancement toward a first-in-human trial</description>
    </item>
    <item>
      <title>Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program</title>
      <link>https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-selected-one-only-134500705</link>
      <guid isPermaLink="true">https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-selected-one-only-134500705</guid>
      <pubDate>Tue, 27 Jan 2026 13:45:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced it has been selected as one of only ten companies worldwide to participate in the Japan Entry Acceleration Program (JEAP), a highly competitive initiative launched by the Japan External Trade Organization (JETRO). JEAP drew approximately 70 regenerative medicine companies from 25</description>
    </item>
    <item>
      <title>Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer</title>
      <link>https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-announces-successful-pre-131500484</link>
      <guid isPermaLink="true">https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-announces-successful-pre-131500484</guid>
      <pubDate>Tue, 06 Jan 2026 13:15:00 GMT</pubDate>
      <description>Regulatory alignment supports rapid progress, tech transfer already underway to accelerate clinical readiness Company on track to initiate first-in-human (FIH) trial for the treatment of ovarian cancer in the second half of 2026 CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the successful completion of its recent Pre-Investig</description>
    </item>
    <item>
      <title>Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer</title>
      <link>https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-presents-preclinical-data-133000553</link>
      <guid isPermaLink="true">https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-presents-preclinical-data-133000553</guid>
      <pubDate>Mon, 08 Dec 2025 13:30:00 GMT</pubDate>
      <description>Positive results of ERNA-101 in ovarian cancer models demonstrated promising survival benefit and immune activation, underscoring the potential for broad oncology applications, including hematologic malignanciesCAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the presentation of new preclinical data on its lead cell therapy cand</description>
    </item>
    <item>
      <title>Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting</title>
      <link>https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-announces-oral-presentation-133000112</link>
      <guid isPermaLink="true">https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-announces-oral-presentation-133000112</guid>
      <pubDate>Wed, 03 Dec 2025 13:30:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that data from its novel cell therapy platform will be shared in an oral presentation at the 67th ASH Annual Meeting, being held December 6-9, 2025 in Orlando, FL. “Being selected to give an oral presentation at ASH is a tremendous honor and a major milestone,” said Sanjeev Luther</description>
    </item>
    <item>
      <title>Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG</title>
      <link>https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-strengthens-scientific-medical-135000198</link>
      <guid isPermaLink="true">https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-strengthens-scientific-medical-135000198</guid>
      <pubDate>Tue, 02 Dec 2025 13:50:00 GMT</pubDate>
      <description>Appointment reinforces clinical and translational depth as Ernexa advances its best-in-class iMSC cell therapy platform into first-in-human trialsCAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the appointment of Dr. Ira S. Winer, M.D., Ph.D., FACOG, to its Scientific and Medical Advisory Board. Dr. Winer is a nationally recogn</description>
    </item>
    <item>
      <title>Ernexa Therapeutics to Present at Oxford Global’s Cell 2025</title>
      <link>https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-present-oxford-global-120000761</link>
      <guid isPermaLink="true">https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-present-oxford-global-120000761</guid>
      <pubDate>Tue, 11 Nov 2025 12:00:00 GMT</pubDate>
      <description>Sanjeev Luther, President and CEO to give an oral presentation and participate in a moderated panel discussionCAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced it will present at Cell 2025, Oxford Global’s premier event, being held on November 11 and 12, 2025 in London, UK. Details of the presentations are as follows: Title: Prep</description>
    </item>
    <item>
      <title>Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials</title>
      <link>https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-reports-strong-quarterly-133500312</link>
      <guid isPermaLink="true">https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-reports-strong-quarterly-133500312</guid>
      <pubDate>Mon, 10 Nov 2025 13:35:00 GMT</pubDate>
      <description>The Company’s operating loss declined by 44% year-over-year, reflecting its continued laser focus on relentless execution and progress in operational excellence Continued progress with lead program, ERNA-101, toward first-in-human Phase 1 study in platinum-resistant ovarian cancer (PROC), anticipated in H2 2026 CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, t</description>
    </item>
    <item>
      <title>Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform</title>
      <link>https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-showcases-strategic-partnership-141500020</link>
      <guid isPermaLink="true">https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-showcases-strategic-partnership-141500020</guid>
      <pubDate>Thu, 06 Nov 2025 14:15:00 GMT</pubDate>
      <description>Access the “What This Means” segment here CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it recently participated in a Virtual Investor &quot;What This Means&quot; segment. As part of the segment, Sanjeev Luther, President and CEO of Ernexa, discussed the Company’s recently announced partnership agreement with Cellipont Bioservices</description>
    </item>
    <item>
      <title>/C O R R E C T I O N -- Cellipont Bioservices/</title>
      <link>https://6ix.com/company/eterna-therapeutics-inc/news/c-o-r-r-e-c-t-i-o-n-cellipont-bioservices</link>
      <guid isPermaLink="true">https://6ix.com/company/eterna-therapeutics-inc/news/c-o-r-r-e-c-t-i-o-n-cellipont-bioservices</guid>
      <pubDate>Wed, 29 Oct 2025 14:32:00 GMT</pubDate>
      <description>Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced it has entered into a collaboration with Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease. The partnership agreement will focus on Engineering, Differentiation, and Production (EDP) activities to advance ERNA-101, Ernexa&apos;s lead cell therapy for the treatment of ovarian cancer,</description>
    </item>
    <item>
      <title>Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell &amp; Gene Meeting on the Mesa</title>
      <link>https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-deliver-company-presentation-123000265</link>
      <guid isPermaLink="true">https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-deliver-company-presentation-123000265</guid>
      <pubDate>Wed, 01 Oct 2025 12:30:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced its upcoming company presentation at the Cell &amp; Gene Meeting on the Mesa, taking place on October 7 in Phoenix, Arizona, and virtually online. “We are honored to participate in the Cell &amp; Gene Meeting on the Mesa, one of the most important gatherings for advancing cell and gene therapies,” said Sa</description>
    </item>
    <item>
      <title>Ernexa Therapeutics President &amp; CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit</title>
      <link>https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-president-ceo-sanjeev-123000396</link>
      <guid isPermaLink="true">https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-president-ceo-sanjeev-123000396</guid>
      <pubDate>Mon, 29 Sep 2025 12:30:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that its President and CEO, Sanjeev Luther, will participate in a featured panel discussion at the upcoming 5th Annual iPSC Drug Development Summit on October 1 in Boston. “Participation in the iPSC Drug Development Summit provides Ernexa the opportunity to contribute to important conversations s</description>
    </item>
    <item>
      <title>Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research</title>
      <link>https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-present-data-oral-123000658</link>
      <guid isPermaLink="true">https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-present-data-oral-123000658</guid>
      <pubDate>Wed, 17 Sep 2025 12:30:00 GMT</pubDate>
      <description>Presentation to highlight preclinical data from the company’s lead cell therapy, ERNA-101, demonstrating potential to reprogram the ovarian tumor microenvironment and advance toward clinical trialsCAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced preclinical data will be presented at the inaugural AACR Special Conference in Cancer Research: Adva</description>
    </item>
    <item>
      <title>Ernexa Therapeutics Provides Update on Operational Excellence and Performance</title>
      <link>https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-provides-operational-excellence-123000568</link>
      <guid isPermaLink="true">https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-provides-operational-excellence-123000568</guid>
      <pubDate>Wed, 10 Sep 2025 12:30:00 GMT</pubDate>
      <description>The company’s operating loss declined by 51% year-over-year, reflecting a laser focus on relentless execution and significant progress in expense reductionCAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today provided an update on its operational excellence and performance for the first half of 2025. The company reported its financial results in its Quarterly</description>
    </item>
    <item>
      <title>Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference</title>
      <link>https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-announces-presentation-h-133000638</link>
      <guid isPermaLink="true">https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-announces-presentation-h-133000638</guid>
      <pubDate>Wed, 03 Sep 2025 13:30:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced it will be featured as a presenting company at the H.C. Wainwright 27th Annual Global Investment Conference, being held September 8–10, 2025. The event will take place at the Lotte New York Palace Hotel in New York City. Virtual participation will be staged simultaneously, with m</description>
    </item>
    <item>
      <title>Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements</title>
      <link>https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-regains-compliance-nasdaq-123000312</link>
      <guid isPermaLink="true">https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-regains-compliance-nasdaq-123000312</guid>
      <pubDate>Wed, 09 Jul 2025 12:30:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it has regained compliance with Nasdaq for continued listing and that its stock will continue to trade on The Nasdaq Stock Market. On July 1, 2025, the company received formal notice from Nasdaq stating that Ernexa has regained compliance with Nasdaq’s minimum bid price requirement under List</description>
    </item>
    <item>
      <title>Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development</title>
      <link>https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-expands-advisory-board-123000575</link>
      <guid isPermaLink="true">https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-expands-advisory-board-123000575</guid>
      <pubDate>Wed, 25 Jun 2025 12:30:00 GMT</pubDate>
      <description>Addition of Dr. Amir Jazaeri and Dr. Anna Jonsson Reflects Ernexa’s Strategic Focus on Ovarian Cancer and Autoimmune Disease ProgramsCAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the expansion of its Scientific Advisory Board to a combined Scientific and Medical Advisory Board as the company advances toward clinical trials in ovarian cancer a</description>
    </item>
    <item>
      <title>Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement</title>
      <link>https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-secures-6-million-123000064</link>
      <guid isPermaLink="true">https://6ix.com/company/eterna-therapeutics-inc/news/ernexa-therapeutics-secures-6-million-123000064</guid>
      <pubDate>Tue, 24 Jun 2025 12:30:00 GMT</pubDate>
      <description>Stockholder-approved financing brings total gross proceeds to $7.1 million; funds to support working capital initiativesCAMBRIDGE, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that the Company completed the second closing under the previously announced securities purchase agreement (the “SPA”) entered into on March 31, 2025 with certain accredited inve</description>
    </item>
  </channel>
</rss>